New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-κB ligand (RANKL)
Open Access
- 31 August 2004
- journal article
- review article
- Published by Elsevier in Experimental Hematology
- Vol. 32 (8) , 685-691
- https://doi.org/10.1016/j.exphem.2004.03.015
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Soluble receptor activator of nuclear factor κB ligand–osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic indexBlood, 2003
- Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the diseaseBlood, 2003
- Human myeloma cells stimulate the receptor activator of nuclear factor-κB ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone diseaseBlood, 2002
- Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor κB ligand on adult T-cell leukemia cellsBlood, 2002
- Myeloma bone diseaseSeminars in Hematology, 2001
- Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cellsBone, 1999
- STAT3 Activation in Stromal/Osteoblastic Cells Is Required for Induction of the Receptor Activator of NF-κB Ligand and Stimulation of Osteoclastogenesis by gp130-utilizing Cytokines or Interleukin-1 but Not 1,25-Dihydroxyvitamin D3 or Parathyroid HormoneJournal of Biological Chemistry, 1999
- Macrophage-Inflammatory Protein-1α Regulates Preosteoclast Differentiationin VitroBiochemical and Biophysical Research Communications, 1999
- Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and ActivationCell, 1998
- Multiple MyelomaNew England Journal of Medicine, 1997